1. Market Research
  2. > Biotechnology
  3. > Biological Therapy Market Trends
  4. > T-Cell Immunotherapy Market, 2015-2030

T-Cell Immunotherapy Market, 2015-2030

  • October 2015
  • -
  • Roots Analysis Private Ltd.
  • -
  • 419 pages

INTRODUCTION
WHO has stated that the number of new cancer cases is expected to rise by 70% in the coming two decades.In the US alone, over one million people are diagnosed with cancer each year.Although cancer therapeutics continues to be one of the most active areas in terms of drug development, there is still a significant unmet need. Specifically, immuno-oncology has been gradually nurtured by researchers over the last several years. Post an evident shift towards the development of therapeutics targeting cancer cells by harnessing immune system components, immunotherapeutics have gained a strong foothold in the pharmaceutical industry. After the early success of Immune Checkpoint Inhibitors, T-cell immunotherapy has emerged as another innovative and potent arm of this market.

Characterised by key features such as target specificity, adaptability and memory, T-cells have been effectively used as tools to mediate an immune response. T-cell immunotherapy is structured into segments comprising of CAR-T, TCR and TIL therapies. Academicians across the globe have significantly contributed by convening the initial research of the candidates; this has served as the framework for several start-ups / established industry players to drive the research forward.

The overall market is expected to make a huge leap over the coming decade. It is also important to highlight that various technology providers, aiming to develop T-cell immunotherapy products with improved efficacy and safety, have developed innovative platforms for engineering of the T-cells. Innovative research, lucrative rounds of VC funding, discovery of several novel targets, growing pipelines directed towards different therapeutic areas and encouraging clinical trial results have emerged as some of the other drivers of this market.

SCOPE OF THE REPORT
The “T-Cell Immunotherapy Market, 2015-2030”report provides an extensive study of the field of T-cell immunotherapy. With no marketed products, this emerging field is still in its infancy; the report provides a comprehensive view of the market segmented into the following three sub-groups: CAR-T therapies, TCR therapies and TIL therapies.

The T-cell immunotherapy market is characterised by a robust and opportunistic pipeline of products targeting both haematological cancers and solid tumours. As mentioned earlier, several research institutes have played a critical role in progression of the technology to its current stage. Post the initial research, industry players have collaborated with non-industry participants to fund the clinical and commercial development of these products. Some late stage products that have emerged out of such collaborations include CTL-019 (Novartis/University of Pennsylvania / The Children’s Hospital of Philadelphia), JCAR017 (Juno Therapeutics / Seattle Children’s Hospital), KTE-C19 and NY-ESO-1 TCR (Kite Pharma / National Cancer Institute), CD19-CAR (Takara Bio / Jichi Medical University) and LN-144 (Lion Biotechnologies / National Cancer Institute). Encouraging clinical results have accelerated the progress of these therapies as they have emerged as one of the most effective ways of leveraging the potential of immune system.

The T-cell immunotherapy market is also seeing a growing interest from several technology providers, especially those with capabilities in genome editing and viral and non-viral gene transfer. In addition, several T-cell immunotherapy companies and technology providers are also developing innovative safety switches to manage known side effects such as cytokine release syndrome and B-cell aplasia.

One of the key objectives of the study is to review and quantify the opportunities laid by the innovative programs of both small and big pharma firms. The unexploited and promising nature of this market supports the hopes pinned on multiple start-ups by several strategic investors and venture capital firms. Amongst other elements, the report elaborates on the following key areas:
- The current state of the market with respect to key players, development stage of pipeline products (both clinical / preclinical) and targeted indications
- Partnerships which have taken place in the recent past covering research and development collaborations, manufacturing agreements, license agreements specific to technology platforms, product co-development and co-commercialisation
- Innovative technological platforms, such as safety switches, which have contributed significantly in overcoming the existing gaps in therapy regimen
- Various investments and grants received by the companies focused in this area
- Therapeutic areas forming the current focus of developers, the gradual drift and opportunity offered by non-oncological therapeutic areas
- Competitive landscape, challenges and expected trend of market evolution within the three sub-segments
- Development and sales potential based on target consumer segments, likely adoption rate and expected pricing

The research, analysis and insights presented in this report include potential sales of several CAR-T therapies, TCR therapies and TIL therapies; this analysis is backed by a deep understanding of key drivers behind the growth. With most products still in the early stage ofdevelopment, we have provided three market forecast scenarios to add robustness to our model. The conservative, base and optimistic scenarios represent three different tracks of industry evolution. All actual figures have been sourced and analysed from publicly available information. The figures mentioned in this report are in USD, unless otherwise specified.

EXAMPLE HIGHLIGHTS
- During the course of our research, we identified over 180 T-cell therapies across various phases of development; CAR-T therapies (56%) are the most common, followed by TCR (25%) and TIL (19%) therapies.
- Research institutions, through investment of time, expertise and effort, have played a critical role in the design and development of novel CAR-Ts, TCRs and TILs. In fact, non-industrial players are involved in the development of around 65% of all the molecules in the pipeline; of these, 23% molecules are being developed jointly with industry participants.
- Kite Pharma is the current flag-bearer; Novartis, Juno Therapeutics, CBMG, Celyad, Lion Biotechnologies, Immunocore and Adaptimmune are some other well-known players. In addition, several start-ups have also emerged; these include (in alphabetical order) AltorBioScience, Applied Immune Technologies, Autolus, Carsgen, Celdara Medical, Eureka Therapeutics, Formula Pharmaceuticals, Mustang Therapeutics, Theravectys, TILT Biotherapeutics and TNK Therapeutics.
- Engineered CAR-Ts with switch technologies are amongst the latest addition to the next-generation of T-cell immunotherapy pipeline. Players are developing CAR-Ts, TCRs and TILs which are more advanced and shall cater to a diverse array of patient needs. The coming few years are likely to witness a wave of innovative and successful T-cell therapies.
- Funding from VC firms and strategic investors has been a key enabler to the market’s growth. Over the last six years, we identified investments close to USD 3 billion across several start-ups and small firms; this trend is unlikely to subside in the near future.
- Overall, we believe the T-cell therapy market will be worth USD 30 billion by 2030, expanding at an annualised growth rate of over 100%; as TCR and TIL therapies gain ground, CAR-T therapies are likely to garner the most attention in near future.

Table Of Contents

T-Cell Immunotherapy Market, 2015-2030
TABLE OF CONTENTS
1 PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2 EXECUTIVE SUMMARY
3 INTRODUCTION
3.1. Chapter Overview
3.2. The Four Pillars of Cancer Therapy
3.3. Immunotherapy: Gaining a Strong Foothold
3.4. Immuno-Oncology (Cancer Immunotherapy)
3.5. Classification of Cancer Immunotherapies
3.5.1. By Mechanism of Action
3.5.1.1. Active Immunotherapy
3.5.1.2. Passive Immunotherapy
3.5.2. By Type of Target
3.5.3. By Approach
3.5.3.1 Activation and Suppression Immunotherapy
3.5.4. By Product Class
3.5.4.1. Monoclonal Antibodies
3.5.4.2. Bispecific Antibodies
3.5.4.3. Cytokines
3.5.4.4. Cell Based Therapies
3.6. T-Cell Therapies: Historical Evolution
3.7. T-Cell Therapies: Key Considerations
3.8. Strategies for Redirection of T-Cells
3.9. Methodologies for Transduction / Transfection of T-Cells
3.9.1. Retroviral Vectors
3.9.2. Lentiviral Vectors
3.9.3. Sleeping Beauty Transposon
3.10. Curative Potential of T-Cell Therapies
3.11. Roadblocks for T-Cell Therapies
4 MARKET LANDSCAPE
4.1. Introduction
4.2. Evolving T-Cell Therapy Space
4.3. T-Cell Therapy: A Promising and Robust Pipeline
4.4. CAR-T Cells Spearhead the T-Cell Market
4.5. Academia Research Leads On-going Activity in the T-Cell Space
4.6. T-Cell Market Poised to Expand Further: Several Molecules in Early Phases of Development
4.7. LimitedSuccess So Far: Restricted to Haematological Cancers/ Solid Tumours
4.8. Active Industry Players in the T-Cell Therapy Market
4.9. CD19 Continues to be the Most Popular Target for CAR-T Therapies
4.10. Targets Well Distributed for TCR Therapies
4.11. Other T-Cell Immunotherapies under Development
5 CHIMERIC ANTIGEN RECEPTOR-T CELL THERAPY
5.1. Introduction
5.2. History of Development
5.3. Current Research Landscape
5.4. Anatomical Layout of Chimeric Antigen Receptor
5.5. Generations of Chimeric Antigen Receptors
5.6. Development of CAR-T Cells
5.7. Lymphodepleting Therapy
5.8. Universal CAR-Ts
5.9. Route of Administration
5.10. Toxicity Issues
5.10.1. Cytokine Release Syndrome (CRS)
5.10.2. On-Target Off-Tumour Toxicity
5.10.3. Encephalopathy and B-Cell Aplasia
5.11. Management of Toxicity Issues
5.11.1. Target Selection
5.11.2. Cell Persistence
5.11.3. Receptor Expression
5.12. CD19: An Attractive Target
5.13. Other Targets
5.14. Challenges Associated with CAR-T Therapy
5.14.1. Competitive Risks
5.14.2. Clinical Risks
5.14.3. Regulatory Challenges
5.14.4. Commercial Risks
5.15. CTL019 (Novartis)
5.15.1. Introduction
5.15.2. History of Development
5.15.3. Development Status
5.15.4. Key Clinical Trial Results
5.15.5. Dosage Regimen, Treatment Cost and Manufacturing
5.16. JCAR (Juno Therapeutics)
5.16.1. Introduction
5.16.2. CAR-T Design
5.16.3. Development Status
5.16.4. Key Clinical Trial Results
5.16.4.1. JCAR014
5.16.4.2. JCAR015
5.16.4.3. JCAR017
5.16.5. Dosage Regimen and Manufacturing
5.17. KTE-C19 (Kite Pharma)
5.17.1. Introduction
5.17.2. Development Status
5.17.3. Key Clinical Trial Results
5.17.4. Dosage Regimen and Manufacturing
5.17.5. Next Generation eACT CAR Candidates
5.18. CD19 CAR (Takara Bio)
5.18.1. Introduction
5.18.2. Development Status
5.18.3. Key Clinical Trial Results
5.18.4. Dosage Regimen and Manufacturing
5.19. EFGRvIII CAR (Kite Pharma)
5.19.1. Introduction
5.19.2. Development Status
5.19.3. Dosage Regimen and Manufacturing
6 T-CELL RECEPTOR (TCR) THERAPIES
6.1. Introduction
6.2. Structure of T-Cell Receptor
6.3. Difference between CAR and TCR
6.4. History of Development
6.5. Current Research Landscape
6.6. Mechanism of Action
6.7. Safety Issues
6.7.1. Insertional Mutagenesis
6.7.2. On-Target Off-Tumour Toxicity
6.7.3. Cross Reactivity Issues
6.7.4. TCR Mismatch Pairing
6.8. Prerequisites of Antigen-Specific T-Cell Receptors
6.9. Identifying Strategies that Enhance the Anti-Tumour Efficacy
6.9.1. Affinity Enhanced TCRs
6.9.2. Soluble TCR Based Biologics
6.10. NY-ESO-1 TCR (Kite Pharma)
6.10.1. Introduction
6.10.2. Development Status
6.10.3. Dosage Regimen
6.11. MAGE A3/A6 TCR (Kite Pharma)
6.11.1. Introduction
6.11.2. Development Status
6.11.3. Dosage Regimen
6.12. JTCR016 (Juno Therapeutics)
6.12.1. Introduction
6.12.2. Development Status
6.12.3. Key Clinical Trial Results
6.12.4. Dosage Regimen
6.13. IMCgp100 (Immunocore)
6.13.1. Introduction
6.13.2. Development Status
6.13.3. Key Clinical Trial Results
6.13.4. Dosage Regimen
7. TUMOUR INFILTRATING LYMPHOCYTES (TIL) BASED THERAPIES
7.1. Introduction
7.2. Historical Background
7.3. Current Research Landscape
7.4. Strategies under Research to Enhance Efficacy
7.5. TIL: A Prognostic Tool for Various Indications
7.6. LN-144 (Formerly Contego) (Lion Biotechnologies)
7.6.1. Introduction
7.6.2. Development Status
7.6.3. Key Clinical Trial Results
7.6.4. Dosage Regimen and Manufacturing
7.6.5. Patent Portfolio
8. MARKET OPPORTUNITY
8.1. Chapter Overview
8.2. Scope and Limitations
8.3. Forecast Methodology
8.4. Overall T-Cell Therapy Market, 2015-2030
8.5. Overall Chimeric Antigen Receptor T-Cell (CAR-T) Market
8.5.1. CTL019 (Novartis)
8.5.1.1. Target Population
8.5.1.2. Sales Forecast
8.5.2. KTE-C19 (Kite Pharma)
8.5.2.1. Target Population
8.5.2.2. Sales Forecast
8.5.3. CD19 CAR-T (Takara Bio)
8.5.3.1. Target Population
8.5.3.2. Sales Forecast
8.5.4. EGFR CAR-T (Cellular Biomedicine Group)
8.5.4.1. Target Population
8.5.4.2. Sales Forecast
8.5.5. CD30 CAR-T (Cellular Biomedicine Group)
8.5.5.1. Target Population
8.5.5.2. Sales Forecast
8.5.6. Anti-CD19 CAR-T VectorTransducedT-Cells (Cellular
Biomedicine Group)
8.5.6.1. Target Population
8.5.6.2. Sales Forecast
8.5.7. Anti-CD20 CAR T VectorTransduced T-Cells (Cellular
Biomedicine Group)
8.5.7.1. Target Population
8.5.7.2. Sales Forecast
8.5.8. CD19 EBV CAR-T (Autolus)
8.5.8.1. Target Population
8.5.8.2. Sales Forecast
8.5.9. EGFRvIII (Kite Pharma)
8.5.9.1. Target Population
8.5.9.2. Sales Forecast
8.5.10. JCAR017 (Juno Therapeutics)
8.5.10.1. Target Population
8.5.10.2. Sales Forecast
8.5.11. JCAR0XX (Juno Therapeutics)
8.5.11.1. Target Population
8.5.11.2. Sales Forecast
8.6. Overall TCR Market
8.6.1. IMCgp100 (Immunocore)
8.6.1.1. Target Population
8.6.1.2. Sales Forecast
8.6.2. NY-ESO-1 TCR (Kite Pharma)
8.6.2.1. Target Population
8.6.2.2. Sales Forecast
8.6.3. HPV-16 E6-TCR (Kite Pharma)
8.6.3.1. Target Population
8.6.3.2. Sales Forecast
8.6.4. NY-ESO-1 TCR (Adaptimmune)
8.6.4.1. Target Population
8.6.4.2. Sales Forecast
8.6.5. ALT-801 (AltorBioScience)
8.6.5.1. Target Population
8.6.5.2. Sales Forecast
8.6.6. WT-1 TCR (Cell Therapy Catapult)
8.6.6.1. Target Population
8.6.6.2. Sales Forecast
8.6.7. JTCR016 (Juno Therapeutics)
8.6.7.1. Target Population
8.6.7.2. Sales Forecast
8.6.8. MAGE A3/A6 (Kite Pharma)
8.6.8.1. Target Population
8.6.8.2. Sales Forecast
8.6.9. MAGE A3 (Kite Pharma)
8.6.9.1. Target Population
8.6.9.2. Sales Forecast
8.7. Overall TIL Therapy Market
8.7.1. LN-144 (Lion Biotechnologies)
8.7.1.1. Target Population
8.7.1.2. Sales Forecast
8.7.2. TIL Therapy (Nantes University)
8.7.2.1. Target Population
8.7.2.2. Sales Forecast
8.7.3. TIL Therapy (Netherlands Cancer Institute)
8.7.3.1. Target Population
8.7.3.2. Sales Forecast
9. KEY THERAPEUTIC AREAS FOR T-CELL THERAPIES
9.1. Chapter Overview
9.2. Introduction
9.3. Haematological Malignancies
9.3.1. Leukaemia and Lymphoma
9.3.1.1. Introduction and Epidemiology: Leukaemia
9.3.1.1.1. Acute Myeloid Leukaemia (AML)
9.3.1.1.2. Chronic Myeloid Leukaemia (CML)
9.3.1.1.3. Acute Lymphocytic Leukaemia (ALL)
9.3.1.1.4. Chronic Lymphocytic Leukaemia (CLL)
9.3.1.2. Introduction and Epidemiology: Lymphoma
9.3.1.3. Current Treatment Landscape
9.3.1.3.1. Targeted Therapies
9.3.1.4. T-Cell Immunotherapy and Research Landscape
9.3.1.4.1. CAR-Ts and Leukaemia/Lymphoma
9.3.1.4.2. TCRs and Leukaemia/Lymphoma
9.3.2. Multiple Myeloma
9.3.2.1. Introduction and Epidemiology
9.3.2.2. Current Treatment Landscape
9.3.2.3. T-Cell Immunotherapy and Research Landscape
9.4. Solid Tumours
9.4.1. Metastatic Melanoma
9.4.1.1. Introduction and Epidemiology
9.4.1.2. Current Treatment Landscape
9.4.1.3. T-Cell Immunotherapy and Research Landscape
9.4.1.3.1. TILs and Metastatic Melanoma
9.4.1.3.2. TIL Research at MD Cancer Research Centre, USA
9.4.1.3.3. TIL Research at Sheba Medical Centre, Israel
9.4.1.3.4. TCRs and Metastatic Melanoma
9.4.1.3.5 CAR-Ts and Metastatic Melanoma
9.4.2. Bladder Cancer
9.4.2.1. Introduction and Epidemiology
9.4.2.2. Current Treatment Landscape
9.4.2.3. T-Cell Immunotherapy and Research Landscape
9.4.3. Kidney Cancer
9.4.3.1. Introduction and Epidemiology
9.4.3.2. Current Treatment Landscape
9.4.3.3. T-Cell Immunotherapy and Research Landscape
9.4.4. Ovarian Cancer
9.4.4.1. Introduction and Epidemiology
9.4.4.2. Current Treatment Landscape
9.4.4.3. T-Cell Immunotherapy and Research Landscape
9.4.4.3.1. CAR-Ts and Ovarian Cancer
9.4.4.3.2. TCRs and Ovarian Cancer
9.4.5. Breast Cancer
9.4.5.1. Introduction and Epidemiology
9.4.5.2. Current Treatment Landscape
9.4.5.3. T-Cell Immunotherapy and Research Landscape
9.4.5.3.1. CAR-Ts and Breast Cancer
9.4.5.3.2. TCRs and Breast Cancer
9.4.5.3.3. TILs and Breast Cancer
9.4.6. Glioblastoma
9.4.6.1. Introduction and Epidemiology
9.4.6.2. Current Treatment Landscape
9.4.6.3. T-Cell Immunotherapy and Research Landscape
10 EMERGING TECHNOLOGIES
10.1. Chapter Overview
10.2. Introduction
10.3. Genome Editing Driving the T-Cell Therapies
10.4. Applications of Genome Editing
10.4.1. Genome Editing Technologies
10.4.1.1. CRISPR/Cas9 System
10.4.1.1.1. Structural Features
10.4.1.1.2. Modularity of the System
10.4.1.1.3. Mechanism of Action
10.4.1.1.4. Targeting Efficiency and Challenges
10.4.1.1.5. Next-GEN CRISPR Technology
10.4.1.1.6. Technology Providers
10.4.1.1.6.1. Editas Medicine
10.4.1.1.6.2 Intellia Therapeutics
10.4.1.1.6.3. CRISPR Therapeutics
10.4.1.2. TALENs
10.4.1.2.1. Structural Features
10.4.1.2.2. Mechanism of Action
10.4.1.2.3. Advantages and Challenges
10.4.1.2.4. Technology Providers
10.4.1.2.4.1. Cellectis
10.4.1.2.4.2. Editas Medicine
10.4.1.3. Endonuclease and megaTAL
10.4.1.3.1. Technology Providers
10.4.1.3.1.1 bluebird bio
10.4.1.4. Zinc Finger Nuclease
10.4.1.4.1. Benefits
10.4.1.4.2. Technology Providers
10.4.1.4.2.1. Sangamo Biosciences
10.5. Designing T-Cell Therapies with ImprovedCharacteristics
10.5.1. Technology for Targeting Multiple Cancers
10.5.1.1. Antibody Coupled T-Cell Receptor, UnumTherapeutics
10.5.1.2. NK Cell Receptor, Celyad
10.5.1.2.1. Long Term Tumour free Survival
10.5.1.2.2. Durable Anti-Tumour Immunity
10.5.2. Technology for Improved Safety
10.5.2.1. Armoured CAR, Juno Therapeutics
10.5.2.2. RheoSwitch Therapeutic System, Intrexon
10.5.2.3. Inducible Caspase9 Safety Switch, BellicumPharmaceuticals
10.5.2.3.1. CaspaCIDe Safety Switch Technology
10.5.2.3.2. CIDeCAR Switch Technology
10.5.2.3.3. GoCAR-T Switch Technology
10.5.2.4. On-Off Switch, Multiple Companies
10.5.2.4.1. Inhibitory CAR (iCAR), Juno Therapeutics
10.5.2.4.2. On-Off Switch, Theravectys
10.5.3. Allogeneic Technology
10.5.3.1. CIK CAR-T Cells, Formula Pharmaceuticals
10.5.3.2. Allogeneic Platform, Celyad
10.5.3.3. Allogeneic Platform, Cellectis
11 VENTURE CAPITAL SUPPORT
11.1. Chapter Overview
11.2. Investors and Innovative Therapies: Trending Together
11.3. Instances of Investments / Grants in T-Cell Therapies
11.4. Growing Venture Capitalist Interest
11.5. Funding Instances: Distribution by Type ofFunding
11.6. Funding Amount: Distribution by Type of Funding
12 COMPANY PROFILES
12.1. Chapter Overview
12.2. Adaptimmune
12.2.1. Company Overview
12.2.2. Financial Information
12.2.3. Product Portfolio
12.2.4. Manufacturing Capabilities
12.2.5. Collaborations
12.2.5.1. Progenitor Cell Therapy
12.2.5.2. Thermofisher / Life Technologies
12.2.5.3. GlaxoSmithKline
12.2.6. Future Outlook
12.3. Altor Bioscience Corporation
12.3.1. Company Overview
12.3.2. Financial Information
12.3.3. Product Portfolio
12.3.4. Patents Portfolio
12.3.5. Collaborations
12.3.5.1. Massachusetts General Hospital and Howard Hughes Medical Institute
12.3.6. Future Outlook
12.4. bluebird bio
12.4.1. Company Overview
12.4.2. Financial Information
12.4.3. Product Portfolio
12.4.4. Collaborations
12.4.4.1. Celgene Corporation
12.4.4.2. Pregenen
12.4.4.3. Five Prime Therapeutics
12.4.4.4. Kite Pharma
12.4.5. Future Outlook
12.5. Cellectis
12.5.1. Company Overview
12.5.2. Financial Information
12.5.3. Product Portfolio
12.5.4. Collaborations
12.5.4.1. CELLforCURE
12.5.4.2. OncoDesign Biotechnology
12.5.4.3. Ohio University
12.5.4.4. Weill Cornell Medical College
12.5.5. Future Outlook
12.6. Cell Therapy Catapult
12.6.1. Company Overview
12.6.2. Product Portfolio
12.6.3. Manufacturing Capabilities
12.6.4. Collaborations
12.6.4.1. UCL and Imperial Innovations
12.6.4.2. Cellular Therapeutics
12.6.5. Future Outlook
12.7. Juno Therapeutics
12.7.1. Company Overview
12.7.2. Financial Information
12.7.3. Product Portfolio
12.7.4. Patent Litigation
12.7.5. Manufacturing Capabilities
12.7.6. Collaborations
12.7.6.1. Memorial Sloan Kettering, Fred Hutchinson CancerCenter, Seattle Children's Research Institute
12.7.6.2. Opus Bio
12.7.6.3. MedImmune/AstraZeneca
12.7.6.4. Stage Cell Therapeutics
12.7.6.5. Editas Medicine
12.7.6.6. Fate Therapeutics
12.7.6.7. X-Body
12.7.6.8. Celgene
12.7.7. Future Outlook
12.8. Kite Pharma
12.8.1. Company Overview
12.8.2. Financial Information
12.8.3. Product Portfolio
12.8.4. Manufacturing Capabilities
12.8.5. Collaborations
12.8.5.1. National Cancer Institute / National Institutes ofHealth
12.8.5.2. Cabaret Biotech
12.8.5.3. NeoStem
12.8.5.4. Amgen
12.8.5.5. Tel Aviv Sourasky Medical Center
12.8.5.6. T-Cell Factory B.V. (TCF)
12.8.5.7. bluebird bio
12.8.5.8. Leukemia and Lymphoma Society
12.8.6. Future Outlook
12.9. Lion Biotechnologies
12.9.1. Company Overview
12.9.2. Financial Information
12.9.3. Product Portfolio
12.9.4. Manufacturing Capabilities
12.9.5. Collaborations
12.9.5.1. Lonza
12.9.5.2. Moffitt Cancer Center
12.9.5.3. National Cancer Institute
12.9.5.4. National Institutes of Health
12.9.6. Upcoming Products: Next Generation TILs
12.9.7. Future Outlook
12.10. Novartis
12.10.1. Company Overview
12.10.2. Financial Information
12.10.3. Product Portfolio
12.10.4. Patent Litigation
12.10.5. Manufacturing Capabilities
12.10.6. Collaborations
12.10.6.1. University Of Pennsylvania
12.10.6.2. Oxford BioMedica
12.10.6.3. Intellia Therapeutics and Caribou Sciences
12.10.7. Future Outlook
12.11. Takara Bio
12.11.1. Company Overview
12.11.2. Financial Information
12.11.3. Product Portfolio
12.11.4. Manufacturing Capabilities
12.11.5. Collaborations
12.11.5.1. Memorial Sloan Kettering Cancer Center
12.11.5.2. Jichi Medical University Hospital
12.11.6. Future Outlook
12.12. Unum Therapeutics
12.12.1. Company Overview
12.12.2. Financial Information
12.12.3. Product Portfolio
12.12.4. Collaborations
12.12.5. Future Outlook
12.13. Other Companies
12.13.1. Bellicum Pharmaceuticals
12.13.2. Cellular Biomedicine Group
12.13.2.1. Product Portfolio
12.13.2.2. Collaborations
13 INTERVIEW TRANSCRIPT
13.1. Chapter Overview
13.1.1. Vincent Brichard, Vice President, Immuno-Oncology, Celyad
13.1.2. Peter Ho, Director, Process Development, Lion Biotechnologies
13.1.3. AinoKalervo, Competitive Intelligence Manager - Strategy and Business Development, Theravectys
14 CONCLUSION
14.1. T-Cell Therapies: Unfurling Another Dimension of Immunotherapy
14.2. Collaborative Efforts of Research and Industry to Drivethe Market
14.3. Undoubtedly CAR-T Therapy is the Current Flag-Bearer
14.4. Haematological Cancers and Solid Tumours are the Key Focus Areas
14.5. Innovative Technological Platforms have Emerged as Vital Enablers
14.6. Anticipated Market Success Backed up by Progressive Pipelines and VC Funding
15. APPENDIX I: TABULATED DATA
APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

LIST OF FIGURES
Figure 3.1 The Four Pillars of Cancer Therapy
Figure 3.2 Differences between Active and Passive Immunotherapy
Figure 3.3 Differences between Specific and Non-Specific Immunotherapy
Figure 3.4 3Es of the Immune System
Figure 3.5 Strategies for Redirecting T-Cells
Figure 3.6 Targeted Therapeutic Areas in the T-Cell Market
Figure 3.7 T-Cell Therapy: Benefits and Roadblocks
Figure 4.1 T-Cell Immunotherapy Pipeline: Distribution by Type of Product
Figure 4.2 T-Cell Immunotherapy Pipeline: Distribution by Type of Developer
Figure 4.3 T-Cell Immunotherapy Pipeline: Distribution by Type of Developer across CAR-Ts, TCRs and TILs
Figure 4.4 T-Cell Immunotherapy Pipeline: Distribution by Phase of Development (Clinical/Preclinical)
Figure 4.5 T-Cell Immunotherapy Pipeline: Distribution by Phase of Development (PI/II/III/Preclinical)
Figure 4.6 T-Cell Immunotherapy Pipeline: Distribution by Phase of Development (PI/II/III/Preclinical) across CAR-Ts, TCRs and TILs
Figure 4.7 T-Cell Immunotherapy Pipeline: Distribution by Target Therapeutic Area
Figure 4.8 T-Cell Immunotherapy Pipeline: Distribution by Target Therapeutic Area across CAR-Ts, TCRs and TILs
Figure 4.9 T-Cell Immunotherapy Pipeline: Active Industry Players in Clinical Development
Figure 4.10 T-Cell Immunotherapy Pipeline: Active Industry Players in Preclinical Development
Figure 4.11 CAR-T Cell Therapy Pipeline: Distribution by Target Antigens
Figure 4.12 TCR Therapy Pipeline: Distribution by Target Antigens
Figure 5.1 Historical Timeline: Development of CAR-T cells
Figure 5.2 CAR-T: Mapping Prominent Researchers
Figure 5.3 Development of CAR-T Cells
Figure 5.4 Challenges Witnessed in CAR-T Therapy
Figure 5.5 CTL019: Industry Sponsored Clinical Trial Design
Figure 5.6 CTL019: Non-Industry Sponsored Clinical Trial Design
Figure 5.7 JCAR Series: Clinical Trial Design
Figure 5.8 JCAR: Planned Clinical Trials
Figure 5.9 KTE-C19: Clinical Trial Design
Figure 5.10 Manufacturing CD19 CAR-T Cells: Process Comparison
Figure 5.11 CD19 CAR: Clinical Trial Design
Figure 5.12 EGFRvIII CAR: Clinical Trial Design
Figure 6.1 TCR: Mapping Prominent Researchers
Figure 6.2 Development of TCR Based Therapies
Figure 6.3 NY-ESO-TCR: Clinical Trial Design
Figure 6.4 MAGE A3/A6 TCR: Clinical Trial Design
Figure 6.5 JTCR016: Clinical Trial Design
Figure 6.6 IMCgp100: Clinical Trial Design
Figure 7.1 TIL: Mapping Prominent Researchers
Figure 7.2 Process of Adoptive T-Cell Therapy Using TILs
Figure 7.3 LN-144: Clinical Trial Design
Figure 8.1 Overall T-Cell Therapy Market (USD Million)
Figure 8.2 T-Cell Therapy Market, Share of Sub-segments: Base Scenario 2020, 2025 and 2030 (USD Million)
Figure 8.3 Overall CAR-T Market Forecast: Base Scenario (USD Million)
Figure 8.4 CTL019: Current Status by Highest Phase of Development
Figure 8.5 CTL019 Sales Forecast: Base Scenario (USD Million)
Figure 8.6 KTE-C19: Current Status by Highest Phase of Development
Figure 8.7 KTE-C19 Sales Forecast: Base Scenario (USD Million)
Figure 8.8 CD 19 CAR-T Sales Forecast: Base Scenario (USD Million)
Figure 8.9 EGFR CAR-T Sales Forecast: Base Scenario (USD Million)
Figure 8.10 CD30 CAR-T Sales Forecast: Base Scenario (USD Million)
Figure 8.11 Anti-CD19 CAR-T Vector Transduced T-Cells Sales Forecast: Base Scenario (USD Million)
Figure 8.12 Anti-CD20 CAR-T Vector Transduced T-Cells Sales Forecast: Base Scenario (USD Million)
Figure 8.13 CD19 EBV CAR-T Sales Forecast: Base Scenario (USD Million)
Figure 8.14 EGFRvIII Sales Forecast: Base Scenario (USD Million)
Figure 8.15 JCAR017 Sales Forecast: Base Scenario (USD Million)
Figure 8.16 JCAR0XX Sales Forecast: Base Scenario (USD Million)
Figure 8.17 Overall TCR Market Forecast: Base Scenario (USD Million)
Figure 8.18 IMCgp100: Current Status by Highest Phase of Development
Figure 8.19 IMCgp100 Sales Forecast: Base Scenario (USD Million)
Figure 8.20 NY-ESO-1 TCR Sales Forecast: Base Scenario (USD Million)
Figure 8.21 HPV-16E6-TCR Sales Forecast: Base Scenario (USD Million)
Figure 8.22 NY-ESO-1 TCR: Current Status by Highest Phase of Development
Figure 8.23 NY-ESO-1 TCR Sales Forecast: Base Scenario (USD Million)
Figure 8.24 ALT-801 Sales Forecast: Base Scenario (USD Million)
Figure 8.25 WT-1 TCR Sales Forecast: Base Scenario (USD Million)
Figure 8.26 JTCR016: Current Status by Highest Phase of Development
Figure 8.27 JTCR016 Sales Forecast: Base Scenario (USD Million)
Figure 8.28 MAGE A3/A6 Sales Forecast: Base Scenario (USD Million)
Figure 8.29 MAGE A3 Sales Forecast: Base Scenario (USD Million)
Figure 8.30 Overall TIL Market Forecast: Base Scenario (USD Million)
Figure 8.31 LN-144 Sales Forecast: Base Scenario (USD Million)
Figure 8.32 TIL Therapy (Nantes University) Sales forecast: Base Scenario (USD Million)
Figure 8.33 TIL Therapy (Netherland University) Sales Forecast: Base Scenario (USD Million)
Figure 9.1 Most Common Types of Leukaemia
Figure 9.2 Leukaemia: Global Epidemiological Distribution
Figure 9.3 Lymphoma: Global Epidemiological Distribution
Figure 9.4 Multiple Myeloma: Global Epidemiological Distribution
Figure 9.5 Melanoma: Global Epidemiological Distribution
Figure 9.6 Bladder Cancer: Global Epidemiological Distribution
Figure 9.7 Kidney Cancer: Global Epidemiological Distribution
Figure 9.8 Ovarian Cancer: Global Epidemiological Distribution
Figure 9.9 Breast Cancer: Global Epidemiological Distribution
Figure10.1 Applications of Genome Editing
Figure 10.2 Emerging Genome Editing Technologies
Figure 10.3 Emerging Design Technologies
Figure 10.4 Properties of Enhanced T-Cell Platform
Figure 10.5 Comparative Landscape: CAR-T Platforms
Figure 11.1 T-Cell Therapies Funding: Cumulative Number of Investments by Year, 2007-2015
Figure 11.2 T-Cell Therapies Funding: Cumulative Amount Invested by Year, 2007-2015 (USD Million)
Figure 11.3 T-Cell Therapies Funding: Distribution of Instances by Type of Funding
Figure 11.4 T-Cell Therapies Funding: Distribution of Amount Invested by Type of Funding (USD Million)
Figure 12.1 Adaptimmune: VC Funding Instances (USD Million)
Figure 12.2 AltorBioScience: VC Funding Instances (USD Million)
Figure 12.3 Cellectis: VC Funding Instances (USD Million)
Figure 12.4 Juno Therapeutics: VC Funding Instances (USD Million)
Figure 12.5 Kite Pharma: VC Funding Instances (USD Million)
Figure 12.6 Novartis: Sales, 2009-2014 (USD Billion)
Figure 12.7 Novartis: Sales by Operating Segments, 2014 (USD Billion)
Figure 12.8 Takara Bio: Sales, 2010-2014 (YEN Million)
Figure 12.9 Takara Bio: Sales by Operating Segments, 2014(YEN Million, %)
Figure 12.10 Unum Therapeutics: VC Funding Instances (USD Million)
Figure 12.11 Treatment Process Followed Using the Antibody Coupled T-Cell Receptor (ACTR) Technology
Figure 14.1 T-Cell Therapy Market Landscape: Industry Participants
Figure 14.2 T-Cell Therapy Market Landscape: Non-Industry Participants
Figure14.3 T-Cell Immunotherapy Market Forecast: Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Autologous Cell Therapy Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Autologous Cell Therapy Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • January 2017
  • by Transparency Market Research

Global Autologous Cell Therapy Market: Overview This report provides in-depth region wise and country wise analysis of the autologous cell therapy market. Stakeholders of this report include manufacturers ...

Top 10 Bioprocess Technology Market by Cell Culture, Cell Expansion, Cell Counting, Cell Line Development, Flow Cytometry, Single-Use Bioprocessing, Biologics Safety Testing, Tangential Flow Filtration, Virus Filtration & Region - Forecast to 2021

Top 10 Bioprocess Technology Market by Cell Culture, Cell Expansion, Cell Counting, Cell Line Development, Flow Cytometry, Single-Use Bioprocessing, Biologics Safety Testing, Tangential Flow Filtration, Virus Filtration & Region - Forecast to 2021

  • $ 5650
  • Industry report
  • January 2017
  • by MarketsandMarkets

The global top 10 bioprocess technology market is expected to reach USD 71.03 billion by 2021 from USD 39.30 billion in 2016, at a CAGR of 12.4% from 2016 to 2021. On the basis of type, the market is segmented ...

Cartilage Repair/ Cartilage Regeneration Market by Treatment modalities, Application, Region - Forecast to 2021

Cartilage Repair/ Cartilage Regeneration Market by Treatment modalities, Application, Region - Forecast to 2021

  • $ 5650
  • Industry report
  • December 2016
  • by MarketsandMarkets

The global cartilage repair/ cartilage regeneration market is projected to reach USD 779.8 million by 2021 from USD 414.6 million in 2016, growing at a CAGR of 13.5% during the forecast period of 2016 ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.